In vitro study of stromal cell defects in myelodysplastic syndromes.

@article{Boudard2003InVS,
  title={In vitro study of stromal cell defects in myelodysplastic syndromes.},
  author={Delphine Boudard and Annie Viallet and Simone Piselli and Denis Guyotat and Lydia Campos},
  journal={Haematologica},
  year={2003},
  volume={88 7},
  pages={827-9}
}
haematologica/journal of hematology vol. 88(07):july 2003 827 in normal erythroid progenitors. This agent, with its four pyrrole rings, was more active than tallimustine2 or hydroxyurea, the drug currently used for HbF enhancement in β-thalassemia and sickle-cell disease.3 In addition to increasing γ-globin mRNA synthesis, this agent also increased β-globin mRNA, but only slightly increased α-globin mRNA. Since these DNA-binding molecules are cytotoxic,2 chemical modifications will be required… CONTINUE READING